Allogene Therapeutics Announces Q2 2025 Financial Report Plans

Author: Caleb Price Updated: 08-06-2025 09:03 AM

Upcoming Financial Results and Update from Allogene Therapeutics

Allogene Therapeutics, Inc. (NASDAQ: ALLO), a biotechnology company focused on developing innovative CAR T therapies, has announced its plans to release its second-quarter financial results and a comprehensive business update. This significant event is scheduled for August 13, 2025, following the market closure. Investors and stakeholders will have the opportunity to join a live audio webcast and conference call at 2:00 p.m. PT/5:00 p.m. ET to gain insight into the company's latest developments.

Live Webcast for Investors

The upcoming conference call will feature an informative listen-only webcast, which will be accessible on the company's official website under the Investors tab. This section will include the News and Events area, where all relevant updates will be provided. After the live session, a replay will be available for approximately 30 days, allowing interested parties to catch up on the insights shared during the call.

Opportunity for Investor Interaction

For those wanting to engage directly during the call, registration is available through a dedicated link designed for submitting questions. Upon registration, participants will receive a personal PIN, ensuring their entry to the discussion. This interactive feature underscores Allogene Therapeutics' commitment to transparency and connection with its investor community.

About Allogene Therapeutics

Allogene Therapeutics is a clinical-stage biotechnology firm spearheading the creation of allogeneic chimeric antigen receptor T (AlloCAR T™) cell products aimed at treating cancer and autoimmune diseases. The company's advanced pipeline includes off-the-shelf CAR T therapies intended for widespread accessibility, allowing patient-specific treatments on demand. Led by an experienced management team in the cell therapy sector, Allogene continues to innovate in providing reliable and scalable solutions for patients.

Corporate Communication

For media inquiries or investment-related questions, Christine Cassiano serves as the Executive Vice President and Chief Corporate Affairs & Brand Strategy Officer at Allogene. Interested persons may contact Christine via email at Christine.Cassiano@allogene.com to discuss relevant matters pertaining to the company's operations and growth trajectory.

Frequently Asked Questions

What is the date of Allogene's Q2 2025 financial results report?

The financial results will be reported on August 13, 2025.

How can investors listen to the webcast?

Investors can access the live webcast via the Investors section of Allogene Therapeutics' website.

Will there be a replay of the conference call?

Yes, a replay will be available for about 30 days following the live event.

Who can register for the conference call?

Anyone interested in asking questions during the conference call can register through the provided link to receive a personal PIN.

What is Allogene Therapeutics’ main focus?

Allogene Therapeutics specializes in developing allogeneic CAR T therapies for the treatment of cancer and autoimmune diseases.

About The Author

Hey there I'm Caleb Price, a writer and financial specialist who loves to assist others in understanding the financial world. Having years of practical experience and a solid background in finance, my area of expertise is converting difficult financial ideas into useful, doable insights for my blog and publications. My goal with my writing is to give readers the information and assurance they need to successfully negotiate their financial journeys.

My ability to interact with a wide range of people—from novices starting their investing journey to seasoned investors looking for new approaches—has come from contributing to several financial blogs. Making money approachable and understandable is my goal; this will enable you to make wise choices and realize your financial objectives. We appreciate you coming along on this path to success and financial empowerment on Investors Hangout.

Contact Caleb Price privately here. Or send an email with ATTN: Caleb Price as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.